Current challenges in Barrett's esophagus
Gary W. Falk, MD
Director, Center for Swallowing and Esophageal Disorders, Department of Gastroenterology, Cleveland Clinic
Address: Gary W. Falk, MD, Department of Gastroenterology, S40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; email@example.com
Dr. Falk has indicated that he has received grant or research support from the Astra-Zeneca and US Endoscopy corporations, and serves as a consultant for the Astra-Zeneca and Merck corporations.
Barrett’s esophagus, a risk factor for esophageal adenocarcinoma, often goes undetected because it has no defining symptoms that distinguish it from gastroesophageal reflux disease (GERD). Yet early recognition is crucial, and development of reliable, cost-effective surveillance methods must be a public health priority. Several promising techniques could lead to more effective prevention, identification, and management of this premalignant lesion.